6533b81ffe1ef96bd12787eb
RESEARCH PRODUCT
Device Therapy for Rate Control: Pacing, Resynchronisation and AV Node Ablation
Thomas RostockDavid M. KayeA. ThiyagarajahJonathan M. KalmanDennis H. LauStephan WillemsPrashanthan SandersDominik LinzMartin K. Stilessubject
Pulmonary and Respiratory Medicinemedicine.medical_specialtyCardiomyopathy030204 cardiovascular system & hematologyCardiac Resynchronization Therapy03 medical and health sciences0302 clinical medicinePharmacotherapyRefractoryHeart RateAtrioventricular node ablationInternal medicineAtrial FibrillationmedicineHumanscardiovascular diseases030212 general & internal medicinebusiness.industryCardiac Pacing ArtificialAtrial fibrillationmedicine.diseaseAtrial LeadHeart failureAtrioventricular NodeCatheter Ablationcardiovascular systemCardiologyObservational studyCardiology and Cardiovascular Medicinebusinessdescription
Atrioventricular node ablation (AVNA) is generally reserved for patients whose atrial fibrillation (AF) is refractory all other therapeutic options, since the recipients will often become pacemaker dependent. In such patients, this approach may prove particularly useful, especially if a tachycardia-induced cardiomyopathy is suspected. Historically, an "ablate and pace" approach has involved AVNA and right ventricular pacing, with or without an atrial lead. There is also an evolving role for atrioventricular node ablation in patients with AF who require cardiac resynchronisation therapy for treatment of systolic heart failure. A mortality benefit over pharmacotherapy has been demonstrated in observational studies and this concept is being further investigated in multi-centre randomised control trials.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-05-08 | Heart, Lung and Circulation |